• ورود به سامانه
      مشاهده مورد 
      •   صفحهٔ اصلی
      • نشریات انگلیسی
      • Asian Pacific Journal of Cancer Prevention
      • Volume 17, Issue 11
      • مشاهده مورد
      •   صفحهٔ اصلی
      • نشریات انگلیسی
      • Asian Pacific Journal of Cancer Prevention
      • Volume 17, Issue 11
      • مشاهده مورد
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells

      (ندگان)پدیدآور
      Mohammadian, JamalSabzichi, MehdiMolavi, OmmoleilaShanehbandi, DariushSamadi, Nasser
      Thumbnail
      دریافت مدرک مشاهده
      FullText
      اندازه فایل: 
      455.5کیلوبایت
      نوع فايل (MIME): 
      PDF
      نوع مدرک
      Text
      Research Articles
      زبان مدرک
      English
      نمایش کامل رکورد
      چکیده
      Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we investigated the combined effects of stattic and docetaxel on the DU145 prostate cancer cell line. Cytotoxicity was evaluated by MTT assay. To understand molecular mechanisms of stattic action, apoptotic related genes including Bcl-2, Mcl-1, Survivin and Bax were evaluated by real-time RT-PCR. Alteration in the expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 genes and Bax/Bcl-2 ratio were investigated via the 2ΔΔCTmethod. The IC50 values for docetaxel and stattic were 3.7 ± 0.9 nM and 4.6±0.8 μM, respectively. Evaluation of key gene expression levels revealed a noticeable decrease in antiapoptotic Bcl-2 and Mcl-1 along with an increase in pro-apoptotic Bax mRNA levels (p
      کلید واژگان
      Antiapoptotic
      combination chemotherapy
      Docetaxel
      monotherapy
      Static

      شماره نشریه
      11
      تاریخ نشر
      2016-11-01
      1395-08-11
      ناشر
      West Asia Organization for Cancer Prevention (WAOCP)
      سازمان پدید آورنده
      Drug Applied Research Center, and Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
      Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
      Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
      Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
      Drug Applied Research Center, and Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

      شاپا
      1513-7368
      2476-762X
      URI
      https://dx.doi.org/10.22034/APJCP.2016.17.11.5031
      http://journal.waocp.org/article_41329.html
      https://iranjournals.nlai.ir/handle/123456789/37643

      مرور

      همه جای سامانهپایگاه‌ها و مجموعه‌ها بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌هااین مجموعه بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌ها

      حساب من

      ورود به سامانهثبت نام

      تازه ترین ها

      تازه ترین مدارک
      © کليه حقوق اين سامانه برای سازمان اسناد و کتابخانه ملی ایران محفوظ است
      تماس با ما | ارسال بازخورد
      قدرت یافته توسطسیناوب